nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

21.09.2023 | Review

Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics

verfasst von: Peipei Li, Fangchao Li, Yanfei Zhang, Xiaoyang Yu, Jingjing Li

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Tumor-infiltrating T cells are promising drug targets to modulate the tumor microenvironment. However, tumor-infiltrating T lymphocytes, as central targets of cancer immunotherapy, show considerable heterogeneity and dynamics across tumor microenvironments and cancer types that may fundamentally influence cancer growth, metastasis, relapse, and response to clinical drugs. The T cell heterogeneity not only refers to the composition of subpopulations but also divergent metabolic states of T cells. Comparing to the diversity of tumor-infiltrating T cell compositions that have been well recognized, the metabolic diversity of T cells deserves more attention for precision immunotherapy. Single-cell sequencing technology enables panoramic stitching of the tumor bulk, partly by showing the metabolic-related gene expression profiles of tumor-infiltrating T cells at a single-cell resolution. Therefore, we here discuss T cell metabolism reprogramming triggered by tumor microenvironment as well as the potential application of metabolic targeting drugs. The tumor-infiltrating T cells metabolic pathway addictions among different cancer types are also addressed in this brief review.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefPubMed

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRef

Coley WB (1910) The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus). Proc R Soc Med 3(Surg Sect):1–48PubMedPubMedCentral

Peske JD, Woods AB, Engelhard VH (2015) Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment. Adv Cancer Res 128:263–307PubMedPubMedCentralCrossRef

Calì B, Molon B, Viola A (2017) Tuning cancer fate: the unremitting role of host immunity. Open Biol 7(4):170006PubMedPubMedCentralCrossRef

Park R, Winnicki M, Liu E, Chu WM (2019) Immune checkpoints and cancer in the immunogenomics era. Brief Funct Genomics 18(2):133–139PubMedCrossRef

Kambayashi Y, Fujimura T, Hidaka T, Aiba S (2019) Biomarkers for predicting efficacies of anti-PD1 antibodies. Front Med (Lausanne) 6:174PubMedCrossRef

Sun C, Mezzadra R, Schumacher TN (2018) Regulation and function of the PD-L1 checkpoint. Immunity 48(3):434–452PubMedPubMedCentralCrossRef

Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood 131(1):58–67PubMedCrossRef

10.

Balch CM, Riley LB, Bae YJ et al (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125(2):200–205PubMedCrossRef

11.

Solis-Castillo LA, Garcia-Romo GS, Diaz-Rodriguez A et al (2020) Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer. Breast Cancer 27(5):837–849PubMedCrossRef

12.

Sharabi A, Tsokos GC (2020) T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol 16(2):100–112PubMedCrossRef

13.

Kishton RJ, Sukumar M, Restifo NP (2017) Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab 26(1):94–109PubMedPubMedCentralCrossRef

14.

Alcazar I, Marques M, Kumar A et al (2007) Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation. J Exp Med 204(12):2977–2987PubMedPubMedCentralCrossRef

15.

Wang R, Dillon CP, Shi LZ et al (2011) The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35(6):871–882PubMedPubMedCentralCrossRef

16.

Chou C, Pinto AK, Curtis JD et al (2014) c-Myc-induced transcription factor AP4 is required for host protection mediated by CD8+ T cells. Nat Immunol 15(9):884–893PubMedPubMedCentralCrossRef

17.

Macintyre AN, Gerriets VA, Nichols AG et al (2014) The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab 20(1):61–72PubMedPubMedCentralCrossRef

18.

Carr EL, Kelman A, Wu GS et al (2010) Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol 185(2):1037–1044PubMedCrossRef

19.

Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC (2008) Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 84(4):949–957PubMedPubMedCentralCrossRef

20.

Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Rathmell JC (2018) Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell 175(7):1780–1795PubMedPubMedCentralCrossRef

21.

Pacella I, Procaccini C, Focaccetti C et al (2018) Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc Natl Acad Sci U S A 115(28):E6546–E6555PubMedPubMedCentralCrossRef

22.

Berod L, Friedrich C, Nandan A et al (2014) De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med 20(11):1327–1333PubMedCrossRef

23.

O’Sullivan D, van der Windt GJW, Huang SC et al (2018) Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 49(2):375–376PubMedPubMedCentralCrossRef

24.

Raud B, Roy DG, Divakaruni AS et al (2018) Etomoxir actions on regulatory and memory T cells are independent of Cpt1a-mediated fatty acid oxidation. Cell Metab 28(3):504–515PubMedPubMedCentralCrossRef

25.

Ma R, Ji T, Zhang H et al (2018) A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8(+) T cells. Nat Cell Biol 20(1):21–27PubMedCrossRef

26.

van der Windt GJ, Everts B, Chang CH et al (2012) Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36(1):68–78PubMedCrossRef

27.

O’Sullivan D (2019) The metabolic spectrum of memory T cells. Immunol Cell Biol 97(7):636–646PubMedCrossRef

28.

Phan AT, Doedens AL, Palazon A et al (2016) Constitutive glycolytic metabolism supports CD8(+) T cell effector memory differentiation during viral infection. Immunity 45(5):1024–1037PubMedPubMedCentralCrossRef

29.

Sukumar M, Liu J, Ji Y et al (2013) Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123(10):4479–4488PubMedPubMedCentralCrossRef

30.

Schenkel JM, Masopust D (2014) Tissue-resident memory T cells. Immunity 41(6):886–897PubMedPubMedCentralCrossRef

31.

Han SJ, Glatman Zaretsky A, Andrade-Oliveira V et al (2017) White adipose tissue is a reservoir for memory T cells and promotes protective memory responses to infection. Immunity 47(6):1154–1168PubMedPubMedCentralCrossRef

32.

Chapman NM, Zeng H, Nguyen TM et al (2018) mTOR coordinates transcriptional programs and mitochondrial metabolism of activated Treg subsets to protect tissue homeostasis. Nat Commun 9(1):2095PubMedPubMedCentralCrossRef

33.

Pacella I, Piconese S (2019) Immunometabolic checkpoints of Treg dynamics: adaptation to microenvironmental opportunities and challenges. Front Immunol 10:1889PubMedPubMedCentralCrossRef

34.

Jin M, Cao W, Chen B, Xiong M, Cao G (2022) Tumor-derived lactate creates a favorable niche for tumor via supplying energy source for tumor and modulating the tumor microenvironment. Front Cell Dev Biol 10:808859PubMedPubMedCentralCrossRef

35.

Holm E, Hagmuller E, Staedt U et al (1995) Substrate balances across colonic carcinomas in humans. Cancer Res 55(6):1373–1378PubMed

36.

San-Millan I, Brooks GA (2017) Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis 38(2):119–133PubMed

37.

Feng Q, Liu Z, Yu X et al (2022) Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat Commun 13(1):4981PubMedPubMedCentralCrossRef

38.

Watson MJ, Vignali PDA, Mullett SJ et al (2021) Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591(7851):645–651PubMedPubMedCentralCrossRef

39.

Ippolito L, Morandi A, Taddei ML et al (2019) Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer. Oncogene 38(27):5339–5355PubMedCrossRef

40.

Xiao Z, Dai Z, Locasale JW (2019) Metabolic landscape of the tumor microenvironment at single cell resolution. Nat Commun 10(1):3763PubMedPubMedCentralCrossRef

41.

Pan M, Reid MA, Lowman XH et al (2016) Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol 18(10):1090–1101PubMedPubMedCentralCrossRef

42.

Bott AJ, Maimouni S, Zong WX (2019) The pleiotropic effects of glutamine metabolism in Cancer. Cancers 11(6):770PubMedPubMedCentralCrossRef

43.

Commisso C, Davidson SM, Soydaner-Azeloglu RG et al (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497(7451):633–637PubMedPubMedCentralCrossRef

44.

Ron-Harel N, Ghergurovich JM, Notarangelo G et al (2019) T cell activation depends on extracellular alanine. Cell Rep 28(12):3011–3021PubMedPubMedCentralCrossRef

45.

Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA (2013) Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol 14(5):500–508PubMedPubMedCentralCrossRef

46.

Sharma MD, Baban B, Chandler P et al (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117(9):2570–2582PubMedPubMedCentralCrossRef

47.

Dugnani E, Pasquale V, Bordignon C, Canu A, Piemonti L, Monti P (2017) Integrating T cell metabolism in cancer immunotherapy. Cancer Lett 411:12–18PubMedCrossRef

48.

Zhao Q, Chu Z, Zhu L et al (2017) 2-Deoxy-d-Glucose treatment decreases anti-inflammatory M2 macrophage polarization in mice with tumor and allergic airway inflammation. Front Immunol 8:637PubMedPubMedCentralCrossRef

49.

Kagoya Y, Nakatsugawa M, Yamashita Y et al (2016) BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J Clin Invest 126(9):3479–3494PubMedPubMedCentralCrossRef

50.

Pearce EL, Walsh MC, Cejas PJ et al (2009) Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460(7251):103–107PubMedPubMedCentralCrossRef

51.

Nabe S, Yamada T, Suzuki J et al (2018) Reinforce the antitumor activity of CD8(+) T cells via glutamine restriction. Cancer Sci 109(12):3737–3750PubMedPubMedCentralCrossRef

52.

Zhong L, Li Y, Muluh TA, Wang Y (2023) Combination of CAR-T cell therapy and radiotherapy: opportunities and challenges in solid tumors (Review). Oncol Lett 26(1):281PubMedPubMedCentralCrossRef

53.

Xu X, Gnanaprakasam JNR, Sherman J, Wang R (2019) A metabolism toolbox for CAR T therapy. Front Oncol 9:322PubMedPubMedCentralCrossRef

54.

Vormittag P, Gunn R, Ghorashian S, Veraitch FS (2018) A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol 53:164–181PubMedCrossRef

55.

Fan TW, Warmoes MO, Sun Q et al (2016) Distinctly perturbed metabolic networks underlie differential tumor tissue damages induced by immune modulator beta-glucan in a two-case ex vivo non-small-cell lung cancer study. Cold Spring Harb Mol Case Stud 2(4):a000893PubMedPubMedCentralCrossRef

56.

Vande Voorde J, Ackermann T, Pfetzer N et al (2019) Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Sci Adv 5(1):eaau7314PubMedPubMedCentralCrossRef

Titel: Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics
verfasst von: Peipei Li
Fangchao Li
Yanfei Zhang
Xiaoyang Yu
Jingjing Li
Publikationsdatum: 21.09.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 11/2023
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-023-03540-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Nomogram for predicting the prognosis of metastatic colorectal cancer patients treated with anti-PD1 therapy based on serum lipids analysis

Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score

Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie